Journal-Clubbing Our Way Through Internal Medicine
Do you also find it hard to follow the medical literature?
Newsletters with tables of contents are hard to get through after having written all your notes and maybe having done a chart dissection.
Welcome to IM Journal Club!
Our mission: to guide you through some of the most interesting internal medicine studies published in the last few weeks and months that you WOULD have liked to or SHOULD have heard about
Target groups: physicians and other clinicians in general internal or family medicine – hospital medicine and primary care – or in an internal medicine subspecialty; biostatisticians, epidemiologists, or data scientists; journal club enthusiasts!
Hidden agenda: to shed some lights on the studies’ methods AND on the context (what was known before, how do the new results change things – so what does this all mean?). We will give you episodes with primers on particularly difficult methods.
We will come out with a new episode every one to two weeks - we'll upload early on Fridays - so you can listen on your commute or on the weekend.
Please subscribe in your favorite podcast app or to our YouTube channel .
Please let us know what we can do better, or what new study we could cover: You can leave a review in your podcasting app, a comment on YouTube, or drop us a line at hello@imjournalclub.com
We are also on social; our email newsletter will be on Twitter: https://twitter.com/IMJournalClub
---
Show Credits
Host: Ben Geisler
Video editor: Fernando Tábora
Methods consultant: Professor Ulrich Mansmann
Advisory group (current): Bijay Acharya, Chang-Berm Kang, Jeffrey L. Greenwald, Jonathan W. Heflin, Kathy May Tran, Marcel Müller, Rahul Ganatra, and Warren Chuang
Supported by LMU Munich’s Institute for Epidemiology, Biometry, and Medical Information Processing
Hosted on Acast. See acast.com/privacy for more information.
Journal-Clubbing Our Way Through Internal Medicine
Do you also find it hard to follow the medical literature?
Newsletters with tables of contents are hard to get through after having written all your notes and maybe having done a chart dissection.
Welcome to IM Journal Club!
Our mission: to guide you through some of the most interesting internal medicine studies published in the last few weeks and months that you WOULD have liked to or SHOULD have heard about
Target groups: physicians and other clinicians in general internal or family medicine – hospital medicine and primary care – or in an internal medicine subspecialty; biostatisticians, epidemiologists, or data scientists; journal club enthusiasts!
Hidden agenda: to shed some lights on the studies’ methods AND on the context (what was known before, how do the new results change things – so what does this all mean?). We will give you episodes with primers on particularly difficult methods.
We will come out with a new episode every one to two weeks - we'll upload early on Fridays - so you can listen on your commute or on the weekend.
Please subscribe in your favorite podcast app or to our YouTube channel .
Please let us know what we can do better, or what new study we could cover: You can leave a review in your podcasting app, a comment on YouTube, or drop us a line at hello@imjournalclub.com
We are also on social; our email newsletter will be on Twitter: https://twitter.com/IMJournalClub
---
Show Credits
Host: Ben Geisler
Video editor: Fernando Tábora
Methods consultant: Professor Ulrich Mansmann
Advisory group (current): Bijay Acharya, Chang-Berm Kang, Jeffrey L. Greenwald, Jonathan W. Heflin, Kathy May Tran, Marcel Müller, Rahul Ganatra, and Warren Chuang
Supported by LMU Munich’s Institute for Epidemiology, Biometry, and Medical Information Processing
Hosted on Acast. See acast.com/privacy for more information.
So, this trial might appear a bit boring and maybe not so relevant – but maybe only at first. What might add to the difficulty reading or interpreting it is the non-inferiority design – and we might to a methods primer on that in the future. However, this trial may be the answer for a very important question: what do we do with patients who are intolerant to higher doses of statins – can a statin-sparing regimen be the answer?
This was a randomized controlled trial of a high-intensity statin, rosuvastatin 20mg daily vs a moderate-intensity statin – 10mg of rosuvastatin daily – plus 10mg of ezetimibe or Zetia. The trial recruited 3,780 patients with atherosclerotic cardiovascular disease and followed them for three years. The primary endpoint was the composite of cardiovascular death, major adverse cardiovascular events, or non-fatal stroke, and was reached in 9.9% in the high-intensity statin group vs 9.1% in the combination group.
Our guest is Christopher P. Cannon, M.D. He is a cardiologist at Brigham and Women’s Hospital in Boston and a professor at Harvard Medical School. He has run major trials of statins and other interventions to prevent major adverse cardiovascular (and cerebrovascular) events, including the IMPROVE-IT study.
References:
Subscribe to our YouTube Channel and mailing list: https://linktr.ee/imjournalclub
Hosted on Acast. See acast.com/privacy for more information.